Contact
Please use this form to send email to PR contact of this press release:
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
TO:
Please use this form to send email to PR contact of this press release:
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
TO: